Canadian consensus guidelines for the diagnosis and management of acromegaly.
Acromegaly is a chronic condition associated with considerably increased morbidity and mortality if left unchecked. In December 2004, a national meeting was held to discuss the diversity in clinical practice across the country in diagnosing and treating patients with acromegaly, as well as to seek consensus on a number of management principles. The group reviewed recent guidelines and discussed issues of diagnosis, treatment, monitoring and treating comorbidities to seek a Canadian consensus on the management of this rare disorder. Consensus was that diagnosis should include clinical and biochemical findings, but is hinged on establishing GH hypersecretion with IGF-I and OGTT testing. Treatment has traditionally included surgical resection or debulking, along with adjunctive medical therapy (primarily somatostatin analogues), if necessary, to normalize GH levels. The option of primary medical therapy in managing this condition has recently emerged and can be justified for non-surgical candidates or for those in whom surgery is not expected to be curative. Overall, improved screening practices and superior epidemiological data are required, since timely diagnosis and appropriate treatment are crucial for reducing the potentially debilitating effects of this chronic, progressive disease. The current evidence also supports the need for long-term follow-up of disease activity and comorbidities in diagnosed patients. A national meeting was held to discuss the diversity in clinical practice across the country in diagnosing and treating patients with acromegaly, as well as to seek consensus on a number of management principles. After brief reviews of the most recent Canadian guidelines and the 2004 guidelines published by the American Association of Clinical Endocrinologists, the group was asked to specifically examine the issues of diagnosis, treatment, monitoring and treating comorbidities and seek a Canadian consensus on practice. This paper summarizes the working group's findings and the points of consensus that were achieved.
Ezzat
Shereen
S
University of Toronto, Toronto, Ontario. sezzat@mtsinai.on.ca
Serri
Omar
O
Chik
Constance L
CL
Johnson
Michelle D
MD
Beauregard
Hugues
H
Marcovitz
Sorana
S
Nyomba
B L Gregoire
BL
Ramirez
Juan Rivera
JR
Ur
Ehud
E
D000172:Acromegaly / Q000097:blood / Q000175:diagnosis / Q000628:therapy*; D002170:Canada; D002648:Child; D003937:Diagnosis, Differential; D005951:Glucose Tolerance Test / Q000592:standards; D006801:Humans; D008403:Mass Screening / Q000592:standards; D016032:Randomized Controlled Trials as Topic